| Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy M Zangari, E Anaissie, B Barlogie, A Badros, R Desikan, AV Gopal, ... Blood, The Journal of the American Society of Hematology 98 (5), 1614-1615, 2001 | 605 | 2001 |
| Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines C Houde, Y Li, L Song, K Barton, Q Zhang, J Godwin, S Nand, A Toor, ... Blood 104 (12), 3697-3704, 2004 | 248 | 2004 |
| High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions A Badros, B Barlogie, C Morris, R Desikan, SR Martin, N Munshi, ... Blood, The Journal of the American Society of Hematology 97 (9), 2574-2579, 2001 | 237 | 2001 |
| Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations ABT Fassas, F Muwalla, T Berryman, R Benramdane, L Joseph, ... British journal of haematology 117 (1), 103-108, 2002 | 206 | 2002 |
| Clinical activity of arsenic trioxide for the treatment of multiple myeloma NC Munshi, G Tricot, R Desikan, A Badros, M Zangari, A Toor, C Morris, ... Leukemia 16 (9), 1835-1837, 2002 | 204 | 2002 |
| Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic … M Zangari, F Saghafifar, E Anaissie, A Badros, R Desikan, A Fassas, ... Blood coagulation & fibrinolysis 13 (3), 187-192, 2002 | 178 | 2002 |
| Tumor cell escape from therapy-induced senescence T Saleh, L Tyutyunyk-Massey, GF Murray, MR Alotaibi, AS Kawale, ... Biochemical pharmacology 162, 202-212, 2019 | 139 | 2019 |
| Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants G Tricot, T Spencer, J Sawyer, D Spoon, R Desikan, A Fassas, A Badros, ... British journal of haematology 116 (1), 211-217, 2002 | 117 | 2002 |
| Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony‐stimulating factor alone KR Desikan, G Tricot, NC Munshi, E Anaissie, D Spoon, A Fassas, A Toor, ... British journal of haematology 112 (1), 242-247, 2001 | 76 | 2001 |
| Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma HC Fung, P Stiff, J Schriber, A Toor, E Smith, T Rodriguez, A Krishnan, ... Biology of Blood and Marrow Transplantation 13 (5), 594-600, 2007 | 75 | 2007 |
| Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation AA Toor, SY Choo, JA Little Bone marrow transplantation 26 (3), 315-320, 2000 | 74 | 2000 |
| Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma J Duus, HI Bahar, G Venkataraman, F Ozpuyan, KF Izban, H Al-Masri, ... Leukemia & lymphoma 47 (7), 1369-1378, 2006 | 73 | 2006 |
| Fractal organization of the human T cell repertoire in health and after stem cell transplantation J Meier, C Roberts, K Avent, A Hazlett, J Berrie, K Payne, D Hamm, ... Biology of Blood and Marrow Transplantation 19 (3), 366-377, 2013 | 61 | 2013 |
| Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma AA Toor, J Ayers, J Strupeck, M Parthasarathy, S Creech, T Rodriguez, ... British journal of haematology 124 (6), 769-776, 2004 | 56 | 2004 |
| Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the … M Kmieciak, D Basu, KK Payne, A Toor, A Yacoub, XY Wang, L Smith, ... The Journal of Immunology 187 (2), 708-717, 2011 | 55 | 2011 |
| Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen‐specific cellular immunity AA Toor, KK Payne, HM Chung, RT Sabo, AF Hazlett, M Kmieciak, ... British journal of haematology 158 (6), 700-711, 2012 | 54 | 2012 |
| ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning A Badros, G Tricot, A Toor, C Morris, C Guo, N Munshi, B Barlogie, ... Transfusion 42 (2), 205-209, 2002 | 52 | 2002 |
| Infections during mobilizing chemotherapy and following autologous stem cell transplantation AA Toor, JA Van Burik, DJ Weisdorf Bone marrow transplantation 28 (12), 1129-1134, 2001 | 47 | 2001 |
| Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding H Le, S Singh, SJ Shih, N Du, S Schnyder, GA Loredo, C Bien, ... Genes, Chromosomes and Cancer 48 (9), 806-815, 2009 | 46 | 2009 |
| Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells KK Payne, RC Keim, L Graham, MO Idowu, W Wan, XY Wang, AA Toor, ... Journal of Leucocyte Biology 100 (3), 625-635, 2016 | 44 | 2016 |
Masoud ManjiliProfessor of Immunology, Virginia Commonwealth UniversityVerified email at vcu.edu
